Shots:
- Chinese NMPA received two IND applications for CT0596 to initiate P-Ib/II trials in r/r multiple myeloma (MM) & primary plasma cell leukemia (pPCL), respectively
- IIT in China showed favorable efficacy as of Aug 31, 2025, with 6/8 evaluable R/R MM pts achieving PR or better (3 CR/sCR, 1 VGPR, 2 PR) at an mFU of 4.14mos. as presented at ASH’25. Also, preliminary data in r/r pPCL showed 2 pts with high disease burden & rapid progression achieved sCR
- CT0596, an allogeneic BCMA-targeted CAR-T therapy developed via CARsgen’s THANK-u Plus platform, incl. gene knockouts (NKG2A, TRAC, B2M) to reduce GvHD & immune rejection, with additional edits to block NK cell-mediated rejection, enhancing safety & efficacy
Ref: PR newswire | Image: CARsgen | Press Release
Related News: CARsgen Therapeutics Presents Trial Data of CT0596 for Relapsed/Refractory Multiple Myeloma (R/R MM) at ASH’25
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
